Sign in
Taking people in South KoreaNo phase

Tracks how often Crohn's disease and ulcerative colitis occur in Seoul

Studies how often inflammatory bowel disease occurs and its course in one Seoul district.

Key facts

Who runs it
Asan Medical Center
Where
Seoul, South KoreaSee the site
Trial code
Registry title
Epidemiology of Inflammatory Bowel Disease in the Songpa-Kangdong District, Seoul, Korea.
Status
Recruiting
People taking part
2,000 people, planned
Started
Dec 2012
Expected to end
Jun 2029
Type of study
Observational
Record updated
13 January 2021

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for Korean people with Crohn's disease or ulcerative colitis in a district of Seoul, to study how common these diseases are and how they progress.

Sex
All sexes can join.
Disease stage
Definite Crohn's disease or ulcerative colitis, diagnosed by set clinical, endoscopic, radiologic and biopsy criteria. For Crohn's disease, the criteria must be met for at least 2 months.

Main reasons for not taking part

  • Inflammatory bowel disease that cannot be classified as Crohn's disease or ulcerative colitis
  • People of ethnic groups other than Korean

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Definite cases of CD and UC; Patients are diagnosed with CD if they meet at least 2 of the following criteria:
  • clinical history of abdominal pain, weight loss, malaise, diarrhea, and/or rectal bleeding
  • endoscopic findings of mucosal cobblestoning, linear ulceration, skip areas, or perianal disease
  • radiologic findings of stricture, fistula, mucosal cobblestoning, or ulceration
  • macroscopic appearance of bowel wall induration, mesenteric lymphadenopathy, and "creeping fat" at laparotomy
  • pathologic findings of transmural inflammation and/or epithelioid granulomas; Only patients who meet these criteria for at least 2 months are included; Patients are diagnosed with UC only if all 3 of the following criteria are present
  • a typical history of diarrhea or blood and pus or both in the stool for longer than 4 weeks
  • a typical sigmoidoscopic or colonoscopic picture with diffusely granular, friable, or ulcerated mucosa without rectal sparing or skip lesions or radiological signs of characteristic continuous granular or ulcerated mucosa
  • characteristic histopathological signs of inflammation on biopsy

Who cannot take part

  • IBD unclassified
  • Ethnic groups other than Korean

This trial is currently available in South Korea.

  • Asan Medical CenterSeoul, South KoreaContact: Suk-Kyun Yang, M.D.Taking people

About the trial

What the trial wants to find out

The purpose of this study is to evaluate the incidence, prevalence, clinical characteristics and prognosis of Crohn's disease and ulcerative colitis over time in a district of Seoul, Korea.

The group in the trial

  • The Songpa-Kangdong cohort of IBD

    Incident cases of IBD in the Songpa-Kangdong district, a well-defined administrative area in Seoul, the capital of Korea, beginning in 1986, when the first patient with IBD was diagnosed, until 2017. For the prevalent cases, the inhabitants with IBD at Dec 31, 2007 in the Songpa-Kangdong district are included.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Epidemiology of Inflammatory Bowel Disease in the Songpa-Kangdong District, Seoul, Korea.
Plain-language title
Tracks how often Crohn's disease and ulcerative colitis occur in SeoulGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
13 January 2021